{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:40:06Z","timestamp":1790732406536,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"publisher","award":["SG193"],"award-info":[{"award-number":["SG193"]}],"id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009520","name":"Rick Hansen Institute","doi-asserted-by":"publisher","award":["G2015\u201012"],"award-info":[{"award-number":["G2015\u201012"]}],"id":[{"id":"10.13039\/100009520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To determine the effectiveness of mirabegron in patients with neurogenic lower urinary tract dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized, double\u2010blind, placebo\u2010controlled study. Canadian patients with spinal cord injury (SCI) or multiple sclerosis (MS) with urinary symptoms and incontinence were recruited. Patients were randomized to mirabegron 25\u2009mg (or an identical placebo) for 2 weeks at which point a dose escalation to mirabegron 50\u2009mg (or an identical placebo) was maintained for 8 weeks. Urodynamics were performed before and after treatment. The primary outcome measure was maximum cystometric capacity (MCC). Intention to treat analysis and ANCOVA models (with adjustment for baseline values) were used and marginal means (MM) are reported; <jats:italic>P<\/jats:italic>\u2010value &lt;0.05 was considered significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen (9 SCI and 7 MS) patients were randomized to mirabegron and 16 (10 SCI and 6 MS) to placebo. At study completion, there was no significant difference in MCC between mirabegron and placebo (MM 305 vs 369\u2009mL, <jats:italic>P<\/jats:italic>\u2009=\u20090.20). There was no significant difference in volume at first neurogenic detrusor overactivity (NDO, MM 167 vs 137\u2009mL, <jats:italic>P<\/jats:italic>\u2009=\u20090.14) and peak pressure of NDO (MM 69 vs 82\u2009cmH<jats:sub>2<\/jats:sub>O, <jats:italic>P<\/jats:italic>\u2009=\u20090.25). There was no significant difference in pad weights or voiding diary parameters. There was a significantly lower symptom burden among those treated with mirabegron (total neurogenic bladder symptom score MM 29 vs 34, <jats:italic>P<\/jats:italic>\u2009=\u20090.047).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among patients with SCI or MS, we demonstrated non\u2010significant trends towards improvement in some urodynamic parameters with mirabegron 50\u2009mg compared to placebo, and a significantly lower neurogenic bladder symptom burden.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.23774","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T09:48:55Z","timestamp":1535708935000},"page":"2810-2817","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A pilot randomized\u2010controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-558X","authenticated-orcid":false,"given":"Blayne","family":"Welk","sequence":"first","affiliation":[{"name":"Department of Surgery and Epidemiology and Biostatistics Western University London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Hickling","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Ottawa Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McKibbon","sequence":"additional","affiliation":[{"name":"St Josephs Hospital London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Radomski","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ethans","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.028"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.036"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11023.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.037"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4541"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.542146"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2015.195"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23566"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20319"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22981"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512474089"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10066"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2007.02.009"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.01.027"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100750"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.22237\/jmasm\/1257035100"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22629"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12215"},{"key":"e_1_2_8_25_1","first-page":"9107","article-title":"Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron","volume":"24","author":"Zachariou A","year":"2017","journal-title":"Can J Urol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.01.002"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12091"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.007"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.03.016"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.033"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64066-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000103274.38694.b1"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.23774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T08:52:54Z","timestamp":1694681574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.23774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1002\/nau.23774"],"URL":"https:\/\/doi.org\/10.1002\/nau.23774","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"2018-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}